Compare Danuglipron (evidence B) and Orforglipron (evidence B) on mechanism, clinical status, safety, and dosing.
Danuglipron (PF-06882961) is a small-molecule, non-peptide oral GLP-1 receptor agonist developed by Pfizer. NOTE: Danuglipron is NOT a peptide — it is a…
Orforglipron (LY3502970) is a small-molecule, non-peptide oral GLP-1 receptor agonist being developed by Eli Lilly. NOTE: Orforglipron is NOT a peptide — it…
Full profiles: Danuglipron, Orforglipron.